Cyclacel Cancer Study Showing Weak Data
August 30th, 2008
Debi wrote an interesting post today on
Here’s a quick excerpt
Cyclacel Pharmaceuticals Inc. said an independent data review committee recommended that the company’s Phase IIb seliciclib study in non-small lung cancer should continue, even though the data probably won’t show an improvement in progression-free survival – the study’s main objective.
Read the rest of this great post here
Posted in